Alf Bernhardt MD
Most oncology biotechs reach their pivotal readout without a medical strategy in place. The KOL relationships are not built. The publication plan does not exist. The MSL infrastructure is on a slide, not in the field.
By the time the gap becomes visible, the launch window is already closing.
I work with Series B and C biotech companies in hematology, oncology and immunology that are building their medical function ahead of a US or EU launch. I have done this before – at Roche, at Seattle Genetics, and at Takeda – and I now work as a Fractional CMO for companies that need that experience without the full-time overhead.
Based in Basel. Working globally.
Business Partners
Health in Focus
25+ years in hematology, oncology and immunology medical affairs — from bench to global launch.
I have built Medical Affairs organisations from zero, led landmark EMA and FDA approvals, and shaped the scientific strategy behind some of the most successful oncology launches in Europe and the US.
I work with biotech and pharma companies that need senior medical leadership — without the overhead.
I integrate AI tools into Medical Affairs workflows — from literature monitoring and medical information to
field documentation and evidence synthesis.
Rachelle Mudrinich, MBA, CDMP, PCM
Marketing Director
